NASDAQ: COYACoya Therapeutics Inc Stock
$5.63+0.26 (+4.84%)
Updated Jun 13, 2025
COYA Price
$5.63
Fair Value Price
$3.40
Market Cap
$94.16M
52 Week Low
$4.65
52 Week High
$10.24
P/E
-5.26x
P/B
2.82x
P/S
29.36x
PEG
N/A
Dividend Yield
N/A
Revenue
$3.69M
Earnings
-$17.14M
Gross Margin
100%
Operating Margin
-484.54%
Profit Margin
-465%
Debt to Equity
0.15
Operating Cash Flow
-$15M
Beta
0.9
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
COYA Overview
Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a Treg-enhancing biologic for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an allogeneic Treg exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company was incorporated in 2020 and is headquartered in Houston, Texas.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine COYA's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
COYA
Ranked#277 of 464
Ranked#277 of 464
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.18 | A | |
| $41.59 | A | |
| $23.53 | A |
Be the first to know about important COYA news, forecast changes, insider trades & much more!
COYA News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how COYA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
COYA ($5.63) is overvalued by 65.81% relative to our estimate of its Fair Value price of $3.40 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
COYA ($5.63) is not significantly undervalued (65.81%) relative to our estimate of its Fair Value price of $3.40 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
COYA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more COYA due diligence checks available for Premium users.
Valuation
COYA fair value
Fair Value of COYA stock based on Discounted Cash Flow (DCF)
Price
$5.63
Fair Value
$3.40
Overvalued by
65.81%
COYA ($5.63) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
COYA ($5.63) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
COYA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
COYA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-5.26x
Industry
-108.97x
Market
31.36x
COYA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.82x
Industry
4.66x
COYA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
COYA's financial health
Profit margin
Revenue
$257.9k
Net Income
-$7.3M
Profit Margin
-2,833.4%
COYA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
COYA's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$38.4M
Liabilities
$5.0M
Debt to equity
0.15
COYA's short-term assets ($38.37M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
COYA's short-term assets ($38.37M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
COYA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.8M
Investing
$0.0
Financing
$19.1k
COYA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
COYA vs Biotech Stocks
Coya Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.